This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Dates for March

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for March:

March 7-9:
Cowen & Co. Annual Healthcare Conference

March 9-13:
National Comprehensive Cancer Network Annual Meeting (NCCN)

March 10:
Human Genome Sciences (HGSI): FDA drug approval decision date for Benlysta in lupus.
Dendreon (DNDN): FDA approval decision for expansion of Provenge manufacturing capacity at New Jersey facility.

March 18-22:
American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

March 24-27:
American Academy of Pain Medicine (AAPM) meeting.

March 26:
Bristol-Myers Squibb (BMY - Get Report): FDA drug approval decision date for Yervoy in melanoma.

March 30 - April 3:
European Association for the Study of the Liver (EASL) annual meeting.

Other potential biotech events in March:

Cell Therapeutics (CTIC): Outcome of FDA appeal meeting for pixantrone in aggressive non-Hodgkin's lymphoma

A.P. Pharma (APPA): Meeting with FDA to discuss requirements for resubmission of APF530 for chemotherapy-induced nausea following last year's rejection letter.

Achillion Pharmaceuticals: (ACHN - Get Report) Top-line results from 28-day, phase IIa study of hepatitis C drug ACH-1625.

Celgene (CELG - Get Report): Top-line results from phase II study of amrubicin in small-cell lung cancer.

Corcept Therapeutics: (CORT - Get Report) FDA approval filing for Corlux in Cushing's syndrome.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.30 -40.00%
ACHN $5.92 -0.67%
BMY $61.08 0.10%
CELG $103.16 2.65%
CORT $3.49 -0.29%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs